His main research concerns Multiple sclerosis, Immunology, Immune system, Internal medicine and Microglia. A large part of his Multiple sclerosis studies is devoted to Acute disseminated encephalomyelitis. Amit Bar-Or has included themes like Placebo, Surgery and Ocrelizumab in his Internal medicine study.
His studies in Ocrelizumab integrate themes in fields like Hazard ratio and Monoclonal. His Microglia research includes elements of Acquired immune system, Neuroimmunology, Neuroinflammation, Monocyte and Innate immune system. The various areas that Amit Bar-Or examines in his Randomized controlled trial study include Gastroenterology, Teriflunomide and Phases of clinical research.
His primary areas of investigation include Multiple sclerosis, Immunology, Internal medicine, Immune system and In patient. His work carried out in the field of Multiple sclerosis brings together such families of science as Clinical trial, Disease, Pathology and Central nervous system, Neuroscience. His work in Antibody, T cell, Antigen, Cytokine and B cell are all subfields of Immunology research.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo, Expanded Disability Status Scale and Ocrelizumab. The concepts of his Placebo study are interwoven with issues in Dimethyl fumarate, Physical therapy and Randomized controlled trial, Surgery. Amit Bar-Or interconnects Inflammation and Cell biology in the investigation of issues within Immune system.
Multiple sclerosis, Internal medicine, Immunology, In patient and Immune system are his primary areas of study. Amit Bar-Or combines subjects such as Ocrelizumab, Clinical trial and Central nervous system, Neuroscience with his study of Multiple sclerosis. In his study, which falls under the umbrella issue of Internal medicine, Dimethyl fumarate is strongly linked to Gastroenterology.
His Immune system research incorporates themes from Flow cytometry, Cytotoxic T cell, Disease and Cell biology. In T cell, Amit Bar-Or works on issues like Cancer research, which are connected to B cell. His Randomized controlled trial research incorporates elements of Placebo and Interferon beta-1a.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
Stephen L. Hauser;Emmanuelle Waubant;Douglas L. Arnold;Timothy Vollmer.
The New England Journal of Medicine (2008)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or.
The New England Journal of Medicine (2012)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
Ping Shen;Toralf Roch;Vicky Lampropoulou;Richard A. O’Connor.
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos;David Li;Peter A Calabresi;Paul O'Connor.
The Lancet (2011)
Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis
Martin Duddy;Masaaki Niino;Femina Adatia;Sherry Hebert.
Journal of Immunology (2007)
B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Tom A. Barr;Ping Shen;Sheila Brown;Vicky Lampropoulou.
Journal of Experimental Medicine (2012)
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Amit Bar-Or;Peter A. J. Calabresi;Douglas Arnold;Clyde Markowitz.
Annals of Neurology (2008)
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
P.J. Waters;A. McKeon;M.I. Leite;S. Rajasekharan.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: